{
  "trial_id": "NCT00252603",
  "overall_assessment": "likely_ineligible",
  "inclusion": [],
  "exclusion": [
    {
      "criterion": "past or present mental disorders",
      "label": "triggers",
      "evidence": "psychotic disorders, mood disorders"
    },
    {
      "criterion": "significant self-injurious behavior",
      "label": "triggers",
      "evidence": "children who have caused visible harm to themselves"
    },
    {
      "criterion": "active seizure disorder",
      "label": "triggers",
      "evidence": "seizures within the past six months"
    },
    {
      "criterion": "clinically significant or unstable medical illness",
      "label": "triggers",
      "evidence": "hematopoietic, cardiovascular disease"
    },
    {
      "criterion": "gastrointestinal, liver, kidney, or other known conditions",
      "label": "triggers",
      "evidence": "interfere with the absorption, distribution, metabolism, or excretion of drugs"
    },
    {
      "criterion": "seizure disorders (active), cerebrovascular disease or brain trauma as etiology of autistic behavior",
      "label": "triggers",
      "evidence": ""
    },
    {
      "criterion": "clinically significant unstable endocrine disorder",
      "label": "triggers",
      "evidence": "hypo- or hyperthyroidism or diabetes"
    },
    {
      "criterion": "recent history or presence of any form of malignancy",
      "label": "triggers",
      "evidence": ""
    },
    {
      "criterion": "significant improvement of autism symptoms and behaviors to current medications",
      "label": "triggers",
      "evidence": "current medications or have only global autism ratings on the CGI of absent, minimal or mild severity"
    },
    {
      "criterion": "global autism ratings are assessed as being absent, minimal or mild",
      "label": "triggers",
      "evidence": ""
    },
    {
      "criterion": "treatment within the previous 30 days with any drug known to have a well-defined potential for toxicity to a major organ",
      "label": "triggers",
      "evidence": ""
    },
    {
      "criterion": "clinically significant abnormalities in laboratory tests or physical exam",
      "label": "triggers",
      "evidence": ""
    },
    {
      "criterion": "likely to require any other psychotropic medication during the study",
      "label": "triggers",
      "evidence": "except clonidine for insomnia (started at least one month prior to entrance into the study), as well as anticonvulsants at a constant dose for stable seizure disorder or, unless otherwise permitted"
    },
    {
      "criterion": "unable to tolerate taper from psychoactive medication",
      "label": "triggers",
      "evidence": "if specified"
    },
    {
      "criterion": "history of hypersensitivity or severe side effects associated with the use of galantamine",
      "label": "triggers",
      "evidence": "or other acetylcholinesterase inhibitors"
    },
    {
      "criterion": "prior treatment with galantamine of 4mg/day for 6 weeks",
      "label": "triggers",
      "evidence": ""
    },
    {
      "criterion": "investigational drugs within the previous 30 days",
      "label": "triggers",
      "evidence": ""
    }
  ],
  "notes": "Patient has Turner syndrome, short stature, delayed puberty and developmental delay. She is obese and mentally retarded.",
  "_meta": {
    "topic_id": "49",
    "trial_id": "NCT00252603",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}